Thermo Fisher Scientific Inc. (TMO) To Go Ex-Dividend on June 14th

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Wednesday, May 22nd, RTT News reports. Shareholders of record on Friday, June 14th will be given a dividend of 0.39 per share by the medical research company on Monday, July 15th. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date is Friday, June 14th.

Thermo Fisher Scientific has increased its dividend by an average of 16.7% annually over the last three years and has increased its dividend every year for the last 7 years. Thermo Fisher Scientific has a payout ratio of 6.4% meaning its dividend is sufficiently covered by earnings. Research analysts expect Thermo Fisher Scientific to earn $23.97 per share next year, which means the company should continue to be able to cover its $1.56 annual dividend with an expected future payout ratio of 6.5%.

Thermo Fisher Scientific Stock Down 1.0 %

NYSE:TMO opened at $585.03 on Friday. The business’s fifty day moving average price is $576.44 and its 200 day moving average price is $545.98. Thermo Fisher Scientific has a 1-year low of $415.60 and a 1-year high of $603.82. The firm has a market capitalization of $223.32 billion, a price-to-earnings ratio of 37.53, a PEG ratio of 2.76 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. On average, sell-side analysts forecast that Thermo Fisher Scientific will post 21.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent research reports. Evercore ISI upped their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Raymond James lifted their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. The Goldman Sachs Group raised their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $607.35.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders sold 32,000 shares of company stock worth $18,486,980 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.